• Sodium Dicloxacillin in Intracellular MSSA Research

  2026-09-18

  A translational framework for using sodium dicloxacillin monohydrate to connect PBP-directed mechanism, intracellular MSSA activity, pH-dependent potency, and free-drug PK/PD design.

• Shufeng Xingbi Therapy in Allergic Rhinitis Rats

  2026-09-18

  A bioRxiv preprint evaluates Shufeng Xingbi Therapy in an ovalbumin-induced rat model of allergic rhinitis, combining nasal immunology, histopathology, serum biomarkers, and 16S rDNA profiling. The findings associate treatment with reduced allergic inflammation, altered gut microbial composition, increased short-chain fatty acids, and suppression of selected Th2-related signaling markers, while leaving causal and translational questions open.

• ROR1 Signaling: From Cancer Biology to Liver Models

  2026-09-17

  A translational framework for using Anti-ROR1 Antibody (Zilovertamab) to investigate Wnt5a signaling, tumor biology, and emerging liver injury hypotheses without overstating the evidence.

• Hexetidine (NSC-17764): From Rinse to Rigor

  2026-09-17

  Hexetidine (NSC-17764) is best understood as a phenotypic, broad-spectrum antimicrobial rather than a single-target inhibitor. This thought-leadership guide connects membrane-level biology, biofilm assay design, oral translation, and the important boundary between antimicrobial activity and antiviral protease inhibition.

• X-press Tag Peptide for RHEB Assays

  2026-09-16

  Build cleaner recombinant RHEB workflows with an N-terminal leader peptide that supports ProBond capture, Anti-Xpress antibody detection, and optional enterokinase removal. This guide connects practical purification decisions with the UBE2F-SAG-RHEB findings while clearly separating assay utility from biological proof.

• Cefazedone: Reading MIC Evidence for Better Assays

  2026-09-16

  Cefazedone (Refosporen) is examined through a practical evidence framework that connects comparative MIC testing with assay design, spectrum interpretation, and cautious PK/PD translation. Learn how to use historical β-lactam data without overstating clinical or experimental conclusions.

• Tyrothricin: From Membrane Action to Translation

  2026-09-15

  A mechanism-first guide to using Tyrothricin as a peptide antibiotic mixture, connecting membrane-disruption assays with lessons from adaptive resistance research in melanoma.

• PA-824: From TB Mechanism to Regimen Strategy

  2026-09-15

  PA-824 is more than a potent tuberculosis research compound: its dual effects on mycolate biosynthesis and respiratory metabolism make it a strategic probe for designing regimens that address replicating, non-replicating, and drug-resistant Mycobacterium tuberculosis.

• Temafloxacin: Applied Assay Workflows

  2026-09-14

  Temafloxacin supports quantitative susceptibility testing, comparative fluoroquinolone studies, and targeted intracellular antibacterial workflows. This guide translates reference-study findings into practical assay setup, optimization, troubleshooting, and cross-application decisions.

• Paroxetine Effects on Thiothixene Pharmacokinetics

  2026-09-14

  The 1997 reference study tested whether short-term paroxetine pretreatment altered thiothixene disposition in healthy volunteers, using a randomized two-period pharmacokinetic design. No measured thiothixene pharmacokinetic parameter changed significantly, supporting the view that CYP2D6 is not a dominant clearance pathway while preserving important uncertainty about longer inhibition and broader patient populations.

• GI 254023X: ADAM10 Inhibitor Workflows

  2026-09-13

  GI 254023X is a selective ADAM10 inhibitor for connecting sheddase activity with endothelial barrier protection and Notch1 pathway readouts. This guide translates product specifications and reference-study principles into practical workflows for HPAEC, Jurkat, and preclinical vascular assays, with troubleshooting guidance for selectivity, solubility, and assay interpretation.

• Rifampin: From Mechanism to Assay Architecture

  2026-09-12

  Rifampin is a rifamycin antibiotic that enables precise bacterial transcription perturbation. This guide advances beyond routine workflows by showing how to connect molecular inhibition, exposure controls, resistance interpretation, and orthogonal assay design.

• Tyrothricin: A Membrane Assay Framework

  2026-09-11

  Tyrothricin is a peptide antibiotic mixture suited to mechanistic studies of microbial membrane injury. This article presents an assay-centered framework that connects membrane readouts with the experimental logic of recent trigeminal ganglion research without overstating translational relevance.

• CD44 Metabolic Rewiring in IDH-Mutant Leukemia

  2026-09-11

  The reference study identifies CD44 as a functional metabolic dependency of IDH-mutant leukemia, linking adhesion signaling to pentose phosphate pathway activity, glycolytic suppression, NADPH production, and sustained R-2HG synthesis. Its isogenic genetic models and combination experiments support CD44 blockade as a mechanistic strategy to investigate resistance to mutant-IDH inhibition in acute myeloid leukemia.

• Amikacin and the New Logic of Resistance Research

  2026-09-10

  Amikacin (BAY416651) can do more than serve as an antimicrobial readout. Paired with carbapenemase localization, conjugation, mobile-element analysis, and strain typing, it helps translational researchers connect ribosomal action with the movement and expression of resistance in high-priority Enterobacterales.

7999 records 1/534 page Next 12345 下5页 Last page